



# NEWSLETTER

of the European Society for Animal Cell Technology

April 2011

## Election of the Executive Committee 2011-2013

### *Online Election*

The 2011 Executive Committee elections will be conducted by using the same electronic voting system which was first implemented successfully in 2007. Both from an administrative standpoint and based on the feedback received by ESACT Members following its implementation, the Executive Committee is confident that the electronic voting system is superior to paper-based methods.

The system guarantees anonymity and integrity of the election process. Each voter receives a personal code which is randomly generated and secretly communicated by the system. The election administrators only see this code on the ballot and each code can be used only once for voting.

### *Who can vote ?*

All ESACT members who had a paid membership for 2011 on April 24 (including honorary members) and who have a correct and valid email in our records.

If you belong to this category and do not receive your voting code by the end of April, please contact us ([admin@esact.org](mailto:admin@esact.org)), so that we check why you have not received it.

### *How can I vote ?*

Complete instructions will be given in an email you will receive on **April 27**. This email is important because it contains your registration code which is absolutely unique and can not be generated again. So if you are planning to vote when you will be in Vienna, after you have met the candidates, please be sure to bring your code with you.

Once you will have received your code by email, you should simply go to following site:

<http://www.campus-vote.com/elections/ORG/ESACT/>

Enter your code in the blank field and fill in your ballot with your preferred candidates !

You will be allowed to vote for up to 4 candidates from the list of 8. At the end of the process, you can also give your feedback concerning the election process and this is anonymous too.

**The election process will open at 19:00 (GMT) on Wednesday, April 27 and close at 18:00 (GMT) on Monday, May 16, 2011.**

**The results will be announced on May 17 at the ESACT General Assembly in Vienna.**

### *OFFICERS FOR THE PERIOD 2011-2013*

(Appointed by the current Executive Committee)

**Chairman:** **Martin Fussenegger**  
ETH Zurich, Switzerland

**Vice-Chairman:** **Hansjörg Hauser**  
HZI, Germany

**Treasurer:** **Stefanos Grammatikos**  
UCB SA, Belgium

**Secretary:** **Paula Alves**  
IBET/ITQB-UNL, Portugal

<b>Contents</b>	<b>April 2011</b>
Election Process	1
Presentation of Candidates	2
New Members	7

### Nicole Borth

After a thorough education in applied biotechnology in Hermann Katinger's group at the University of Applied Life Sciences, Vienna, Austria (also known as "BOKU"), Nicole Borth is currently a Professor of Cell Biology and Cytometry at the Department of



of Biotechnology at BOKU. Her research focuses on the establishment of analytical and sorting methods to characterise and to improve production cell lines with respect to high production rates and cellular performance. Her group has developed methods to analyse the properties of individual cells, including specific protein secretion rate, which can be used to sort for high producers or cells with enhanced properties. They also lead to a more comprehensive understanding of the molecular machinery that enables a cell to be a good production factory for biotherapeutic proteins. This includes factors that contribute to high yield based on productivity and growth, but also to protein quality attributes. The methods used in an integrative manner are transcriptomics, miRNA arrays, proteomics and flow cytometry / cell sorting. The goal is to understand the molecular basis and regulation of such process and quality relevant cellular properties and to apply this knowledge both to cell line development and process optimisation.

Nicole Borth is a long time member of ESACT and also of the International Society of Analytical Cytometry and of the European Federation of Biotechnology. Together with Hermann Katinger she is co-chair of the ESACT 2011 Vienna Meeting.

#### Motivation statement

After many years as a "silent" member of ESACT, I have had the pleasure of getting a close-up view of the workings of ESACT by attending the executive committee meetings, in preparation of the 2011 meeting. What has enchanted me most in this society was its open readiness to embrace new developments and technology paired with a sense of tradition and continuity, its endeavour to achieve open and fruitful communication across different disciplines, all with the intent to create and enable solutions to the challenges we are faced with in the use of mammalian cells. During the last three years I have had the pleasure of meeting many people who, upon hearing

that I am organising the next ESACT meeting, have all been very helpful and forthcoming, as though being the ESACT meeting chair was a recommendation by its own. Now with most of the organising challenge behind me, I would like to stay involved with this society and contribute towards maintaining its openness and up-to-dateness in the future, both by providing an interface between academic research and industrial challenges and by making available the contacts and experiences I have gained over the last few years.

### Alan Dickson

Alan Dickson is currently Director of the Centre of Excellence in Biopharmaceuticals (CoEBP; <http://www.coebp.ls.manchester.ac.uk>) and is Professor of Biotechnology in the Faculty of Life Sciences at the University of Manchester (<http://www.ls.manchester.ac.uk>).



Alan undertook his BSc and PhD at the University of Edinburgh, before moving to a Research Fellowship at the University of Kent and, subsequently, to the University of Manchester. His research has focused on the regulation of cell function (in terms of metabolic, protein and gene targets) in cells used as hosts for recombinant gene expression. This covers technologies that span from nucleus to secretion apparatus and the relationship of the host cell to the pipeline for generation of functional biopharmaceuticals. In the early 1990's, Alan started a series of fruitful collaborations with commercial partners in relation to mammalian cell hosts for protein harvest and this continues today through the Bioprocessing Research Industry Club (BRIC; <http://www.bbsrc.ac.uk>) and via individual collaborations. Alan is a frequent speaker at international conferences and publishes in/reviews for sector-specific journals.

#### Motivation statement

From an academic viewpoint, the industrial-academic interaction provides fascinating opportunities to pursue unique research activities which have the potential to generate real impact. This perception has strengthened since my initial discussions with prospective industry partners in the early 90's and is arguably even more relevant now than then, with widening of interest in industrial/academic collaborations. I served in various posts with ESACT-UK (through to Chair; reflecting

within the UK community the lead provided by ESACT) over the decade from 1992 before taking on senior management roles within the Faculty of Life Sciences, as Dean for Graduate Education and Dean for Communications. The CoEBP (set up just over 12 months ago) advises and co-ordinates the initiation and development of industrial-academic interactions for staff at the University of Manchester in the area of biopharmaceuticals and their production. This continues my interests in networking strong collaborations around the complementary strengths and visions of industry and academia, the introduction of new expertise to address the on-coming scientific challenges and the development of young researchers who will have the appropriate skills sets to secure the future. I believe that my vision for the sector is a reflection of that of ESACT and I hope to be able to use my experience to aid ESACT achieve its aims over the coming years.

## Francesc (Quico) Gòdia



Professor of Chemical Engineering at Universitat Autònoma de Barcelona, Spain. Research activity focused on the field of Biotechnology and Biochemical Engineering, and more specifically in the culture of mammalian cells for the production of proteins with interest in

diagnostic and therapy of diseases, and the cellular, metabolic and tissue engineering. Work in the development of industrial fermentation processes, immobilized biocatalysts, bioreactor design, and the development of biological life support systems for long term manned missions in Space. Co-founder of the spin-off company HEXASCREEN Culture Technologies, focused on the development of a platform of minibioreactors for screening in Biotechnology.

Became interested to contribute to ESACT since attending his first ESACT meeting in 1992. Served on the ESACT Executive Committee for several years, and as Chairman of the 18<sup>th</sup> ESACT Meeting held in Granada in 2003.

President of the Spanish Society for Biotechnology from 2002 to 2006. Member of the Executive Board of the European Federation of Biotechnology since 2005.

## Motivation Statement

I have enjoyed working for ESACT during a number of years, including organising General Meetings (Granada 2003), and I would like to keep contributing to and increasing the activities of our Society. Particularly, in addition to the support I could provide to future meetings organisers, I would like to explore the organisation of training activities on Animal Cell Technology.

## Hitto Kaufmann



Dr Hitto Kaufmann is currently the Vice President Process Science Germany within the global Biopharmaceutical division of Boehringer Ingelheim. His department covers all aspects of developing mammalian cell culture processes for manufacturing therapeutic proteins including vector and cell line generation, upstream and downstream process

development, formulation and aseptic fill-process development and scale-up of these processes. The unit also supplies material for pre-clinical studies and operates a cGMP clinical manufacturing facility for drug substance and drug product from 400L and 2000L cell culture scales. Before this Dr. Kaufmann was responsible for upstream development at the Biberach site as Director Upstream Development in 2008 and from 2010 onwards as a Global Head of Mammalian Cell Culture Processes. He joined Boehringer Ingelheim in 2003 as Associate Director Cell Biology.

In a previous appointment he worked as a research scientist at the Walter and Eliza Hall Institute in Melbourne, Australia identifying novel drug targets involved in apoptosis. He received his doctorate from the ETH Zürich working on improved production processes in CHO cells.

Dr. Kaufmann is Member of the Advisory Board of the Society for Biological Engineering as of Jan 2009 and several European committees in the field of biotechnology. He furthermore served as a member of the editorial board of Journal of Biotechnology between 2005 and 2010.

## Sadettin Ozturk

Dr. Sadettin Ozturk is currently the head of process and analytical development at Mass Biologics in Boston, USA. He has had a long career in cell culture process development, technology transfer, product licensing, and commercial manufacturing. His early contributions to the field focused on applying chemical engineering principles and process control strategies to the optimization and scale-up of cell culture processes. The scope of his work has expanded over the years, but it has always been focused on advancing cell technology. He was responsible for the development of numerous cell culture based processes and novel technologies that helped not only the companies that he worked for (Verax, Bayer, GlaxoSmithKline, and Johnson & Johnson), but contributed to the rest of the field through his numerous presentations and publications. Sadettin led process development activities and played a key role in the licensing and commercialization of two monoclonal antibodies, Stelera, and Simponi. In addition, he transferred and supported the commercial manufacturing of Kogenate and BeneFix. Sadettin has published numerous research articles, given presentations, delivered keynote lectures, and edited books. He is a member of several societies including ESACT, American Association for the Advancement of Science, New York Academy of Sciences, American Chemical Society, and American Institute of Chemical Engineering. Sadettin is involved in these scientific organizations and other community activities by serving on their Scientific Advisory Boards and organizing meetings and sessions. He has served Biochemical Technology (BIOT) division of American Chemical Society as the Division Chair, and then as a Councilor. He co-authored a well-respected book in the field entitled *Cell Culture Technology for Pharmaceutical and Cellular Therapies*. Sadettin also serves on Editorial and Review Boards for several journals and other publications.




### Motivational Statement

As a long time ESACT member and as an active professional in the field of cell culture technology, I am delighted to be a candidate for Executive Committee membership. I am proud to see the evolution of the field over the years and the impact of our activities on cell culture process development and product discovery for human health. Due to our hard work and dedication, we now have extremely productive, scalable and cost-effective processes, several blockbuster products, and have an established

industry. Over my 20 years of career, I have witnessed a lot of exciting development in the area, met plenty of people, made lots of friends, made contributions and learned a lot from others. To sum it up, I have been having fun and ESACT played a major role in my professional and personal life. Among all of the societies I am involved in, ESACT has been special as it perfectly balanced technical and social interactions. Every ESACT meeting I have attended left with me great memories and helped me to grow professionally. I want to have the spirit of ESACT continue namely to play a part in everyone's career development and to provide a platform for science, friendship, and fun. I have the energy, enthusiasm, and experience to help ESACT maintain the leadership position as a premier society for cell culture, to expand globally, and to prepare the industry for new challenges and opportunities. As a member of Executive Committee, I will make the best use of my experience, networking, and my organizational skills that I gained from other organizations. It will be fun and I am looking forward to it!

## E. Terry Papoutsakis

Prof. Papoutsakis is a native of Greece, where he received his Diploma in Chemical Engineering, from the National Technical University of Athens. His MS and PhD are from Purdue University, W. Lafayette, IN, USA.



His career in cell culture engineering and stem-cell biotechnology spans over 25 years of continuous activity with over 50 PhD students, 15+ postdoctoral fellows and numerous MS students. His publication list includes over 200 papers and book chapters. He served as Editor in Chief for *Biotechnology & Bioengineering* for 6 years and several more as Associate Editor. He serves or served on the Editorial Boards of several journals in the biotechnology arena. He has organized or contributed to the organization of numerous international conferences. His contributions have been recognized by many awards including the 2004 Merck Cell-Culture Engineering award, the Amgen Biochemical Engineering Award, the 2003 Alpha Chi Sigma Award of the American Institute of Chemical Engineers (AIChE), and the 1998 Marvin Johnson Award of the American Chemical Society. He is a Fellow of the American Association for the Advancement of Science (AAAS), and a Founding Fellow of the American Institute of Medical and Biological Engineers. He currently holds the Eugene DuPont Chair at the University of Delaware. Prof.

Papoutsakis's laboratory focuses on the study and modification of regulatory networks that control key cellular programs such as stem-cell differentiation and plasticity, megakaryopoiesis, and apoptosis. The research involves interdisciplinary work in the areas of cell-culture engineering, biochemical engineering, systems biology, metabolic engineering, experimental and computational genomics, stem-cell biology, and hematology. By combining state-of-the-art microarray and genomic analysis techniques with multiparametric flow cytometry, molecular biological tools and cellular physiology, the Papoutsakis Group aims to unravel the exquisitely crafted interplay of cellular processes that allow the exploration of cells for beneficial applications from Regenerative Medicine to Industrial Biotechnology. A growing activity in the lab is the exploration of cell-cycle regulators and miRNAs in the control of hematopoietic differentiation fates, such as polyploidization vs. apoptosis in the development of megakaryopoiesis for platelet generation and *ex vivo* platelet production.

## Motivation Statement

I have been associated with ESACT since its early formative years going back to the late 1980s, and have attended many of the ESACT meetings starting with the 1988 meeting in Knokke. My career has been shaped by the scientific and technological ideas that have been presented and fermented in these ESACT meetings. I have made many friends through ESACT and I now feel that I can give back to ESACT drawing from the experience that I have gained through the years. I feel that I can contribute both in terms of directions in research and technology development, but also in education, training, and outreach to ensure the availability of scientific growth and professional opportunities for the new generation of scientists and cell culture engineers. I am also looking forward to opportunities to provide organizational know-how to ESACT, with emphasis on ESACT awards.

## Jae Sly

Jae Sly has successfully worked in the biopharmaceutical industry for over 15 years. Her Consulting Business: Strategic BioPharm Consulting, Inc., maintains a Domestic and International portfolio of various companies in the Drug Discovery, New Cell Technologies, Stem Cell Separation Systems, Stem Cell products, Vaccine and the Biomanufacturing



Industry. Jae provides opportunities for Strategic Alliances, Networking, Business Development and Marketing. Over the last several years, Jae has developed numerous contacts to expand Grants and Partnering in the US with NIH, BARDA and DARPA. Jae Sly is an active Board Member for various Start-ups and well networked in the VC community. Jae attended University of Hawaii for her Undergraduate studies in Biology and progressed on to her PhD program in Immunology at the University of WA and a MBA from San Diego State University.

I have had the pleasure of participating in the ESACT organization as an exhibitor, a member and most of all a presenter. I feel that the ESACT organization is firmly grounded in the proliferation and encouragement of new cell technologies and processes. As of 2010, I was given the opportunity (by the ESACT Committee) to Design and Administrate the ESACT 2011 Conference Website, [WWW.ESACT2011.COM](http://WWW.ESACT2011.COM).

As a member, I have sought to extend the ESACT message to US companies and expand the membership. I have delivered individuals and companies that I feel will bring synergy and further exposure of technology to our organization. I have also been a champion to the support of ESACT, enrolling companies for sponsorship and exhibition. I have on more than one occasion, assisted in review and submission of abstracts, to facilitate the message of new technologies. I would like to utilize my network to act as a liaison to the US Companies, the Stem Cell community and expand the Industry awareness of cell culture technology as a tool in Stem Cell Research. Additional, I would like to contribute my strengths in marketing to optimize the participation of members, exhibitors and attendees in the ESACT Conferences. I bring an ability to develop infrastructure that can streamline integration and expand capabilities of ESACT. My appointment to the Executive Committee would afford me the ability to expand my efforts towards growing our Organization.

## David (Xiaojian) Zhao

Dr. David (Xiaojian) Zhao is currently the director of R and D at EMD Chemicals, an affiliate of Merck KGaA. He is currently leading cell culture development effort in Merck KGaA. Before joining EMD Chemicals, He has led cell culture technology and media development at



at Invitrogen, a part of Life Technologies for six years. Dr. Zhao has improved recombinant protein and vaccine production with new cell line development, media optimization and feeds using mammalian cell culture. He managed the cell culture product portfolio for annual multi-million dollar new product revenue of bioproduction business and launched over 10 products at Invitrogen. He has evaluated and transferred many new technologies to Invitrogen and developed Invitrogen's cell culture technology platforms

Dr. Zhao received a Ph.D. in Biochemistry from Colorado State University at Fort Collins of Colorado and postdoctoral trainings in molecular biology, protein chemistry and immunology at University of Colorado and the Blood Research Institute of Southeast Wisconsin. His research efforts were focused on genetics, immunology and protein structures.

Dr. Zhao have over 15 year industrial experience on cell culture, media development, process development, genomics, proteomics, bioinformatics, assay development, protein chemistry, enzymology, automation and instrumentation. Prior to Invitrogen, he has worked at Amersham Pharmacia, Orchid Biosciences and US Genomics. Dr. Zhao has launched over 50 biotechnical products and published over 25 papers during his career. He has 5 patents in assays, instruments and microarray area. Dr. Zhao has presented in many international conferences and workshops.

### **Motivation Statement**

I have always enjoyed attending and participating in ESACT meetings and I truly believe that this organization plays an important role in the advancement of the cell culture and process development. I hope my leadership and experience can be useful for ESACT. I would also like to provide my input to ESACT that are complementary and aligned in

serving the interests of the global cell culture community. Through my contribution, I hope to make ESACT to continuously organize the strong and scientifically-driven ESACT conferences. With my extensive network of professional contacts on both sides of the Atlantic, I will do my best to improve information exchanges and collaborations through many infrastructures in ESACT organization. I will also work hard to be sure that these ESACT meetings and this organization play a key role in the development of the next generation of leaders and talents in cell culture field to meet the challenges and needs for cell culture technology in the future.

## New Members

ESACT welcomes the following new members (last 12 months)

New Members are kindly reminded to pay their subscription very quickly, as described in the confirmation letters received by email, especially if you are attending the ESACT 2011 Meeting.

Al-Fageeh Mohamed	King Abdulaziz City for Science and Technology
Andersen Mikael Rørdam	Technical University of Denmark
Bardor Muriel	bioprocessing Technology Institute (BTI)
Bartsch Thorsten	Labor Dr. Merk & Kollegen GmbH
Becker Jennifer	Bielefeld University
Beckmann Tim	Bielefeld University
Böhm Ernst	Baxter
Brinkrolf Karina	Bielefeld University
Brockmann Jörg	MorphoSys AG
Carpio Melisa	Takeda San Francisco
Castro Rute	Instituto de Biologia Experimental e Tecnológica/Instituto de Tecnologia Química e Biológica-UNL
Choi Eun Yeong	aprogen
Choo Andre	Bioprocessing Technology Institute
Clemens Christoph	Boehringer Ingelheim Pharma GmbH&Co. KG
Courtes Franck	Bioprocessing technology institute
Cunningham Michael	EMD Millipore
Di Nino Dana	Pfizer
dickson alan	University of Manchester
Diepenbroek Bas	Crucell
Dodson Elizabeth	BD Biosciences
Droms Kurt	Pfizer Corporation
Duret Valérie	Glenmark Pharmaceuticals S.A.
Ebert Sybille	Rentschler Biotechnologie GmbH
Eibl Dieter	Zurich University of Applied Sciences
Eibl Regine	Zurich University of Applied Sciences
Etcheverrigaray Marina	Universidad Nacional del Litoral. Facultad de Bioquímica y Ciencias Biológicas
Fickers Patrick	Université Libre de Bruxelles
Geleick Detlef	Becton&Dickinson
Gordijn Roel	ATMI Lifesciences
GREGOIRE Anne	CYTHERIS
Gupta Sushil	INTAS Biopharmaceuticals Ltd.,
Hansen Bent	Svanholm.com
Harmsen Mareike	UCB
Hartmann Catharina Isabella	Novo Nordisk A/S
Haseloff Annika	TeutoCell AG
Hayward Andrew	Broadley-James Ltd
Heine Markus	Rentschler Biotechnologie GmbH
Hicks Victor	VHSH, LLC
Hiller Gregory	Pfizer, Inc.
Ho Ying Swan	Bioprocessing Technology Institute
Hörnsten Gunnar	CEFFORT AB
Hübel Tanno	Miltenyi Biotec
Huber Robert	Sandoz
Hundt Boris	IDT Biologika GmbH
Jennings Carmel	Pfizer
Kelm Jens Michael	InSphero AG
Kessler Thomas	Nova Biologics
Kildegaard Helene Fastrup	Technical University of Denmark
Kim Jeeyon	KAIST

## European Society for Animal Cell Technology

---

Kim Yeon-Gu	KRIBB
Klausing Sandra	Bielefeld University
Koenitzer Jennifer	Process Science
Konetschny Christian	Baxter Innovations GmbH
Krämer Oliver	Bielefeld University
kshirsagar rashmi	Biogen Idec
Kumar Sampath	Pfizer Inc.
Lee Eun Gyo	KRIBB
Leonard Mark	Pfizer
Lewis Gareth	Medimmune
Loo Bernard	Bioprocessing Technology Institute
MARC Annie	Centre National de la Recherche Scientifique (CNRS)
Matic Sandra	CMC Biologics A/S
Melville Mark	Pfizer
Merk Walter	Labor Dr. Merk & Kollegen GmbH
Michel Patrik	EPFL
MITTAL ROCHAK	NATIONAL INSTITUTE OF TECHNOLOGY KARNATAKA
Molloy Anne Marie	Pfizer
Müller Christian	Symphogen
nadine kochanowski	UCB
Paschen Stefan	AbD Serotec, MorphoSys AG
Pereira Carlos	Instituto Butantan
Piras Graziella	Life Technologies
Pluschke Jörn	Miltenyi Biotec GmbH
Rantam Fedik	ITD-UNAIR
Rasmussen Søren Kofoed	Symphogen A/S
Rau Tiffany	Pall Corporation
RAUSCH Christian	UCB Pharma S.A.
Reed Sarah	University of Kent
Reiter Manfred	Baxter Innovations GmbH
Rodriguez Jose	Novartis Animal Health
Roy Sylvain	Baxter Bioscience
Sabourin Michelle	Life Technologies
Santos Mariana	Instituto Butantan/Recepta Biopharma
Sathasivam Suyamburam	DSM Biologics
Schneider Falk	DASGIP AG
Schriebl Kornelia	Bioprocessing Technology Institute
Segura Maria Mercedes	Universitat Autònoma de Barcelona
Serpieri Flávia	Libbs Farmacêutica
Shen Xiao	EPFL
Skoging-Nyberg Ulrica	RecipharmCobra Biologics
Somerville Linda	Self employed
Song Frank	EMD Millipore
Stipsitz Claudia	Virusure GmbH
Subashi Timothy	Pfizer Inc.
Teixeira Ana	IBET-ITQB/UNL
Tolstrup Anne B.	Symphogen A/S
Vallez Florentina	Baxter Bioscience
Voedisch Bernd	Novartis Institutes for Biomedical Research
Vonach Bénédicte	Novartis pharma
Welser Franz Xaver	EMP Genetech
Widayati Diah Tri	Faculty of Animal Science, Gadjah Mada University
Woppmann Barbara	Biogen Idec
Wynne John	Merck Millipore
zhang lin	Pfizer
Zhao Xiaojian (David)	EMD/Merck KGaA
Ziegler Thierry	sanofi-aventis